Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value
-
Shares outstanding
-
83.1M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
11.1M
-
Shares change
-
+3.33M
-
Total reported value, excl. options
-
$35.4M
-
Value change
-
+$10.8M
-
Put/Call ratio
-
1.59
-
Number of buys
-
43
-
Number of sells
-
-15
-
Price
-
$3.20
Significant Holders of Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) as of Q4 2024
76 filings reported holding CKPT - Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value as of Q4 2024.
Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.1M shares
of 83.1M outstanding shares and own 13.31% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (4.46M shares), VANGUARD GROUP INC (1.9M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (479K shares), GEODE CAPITAL MANAGEMENT, LLC (445K shares), WEALTH ENHANCEMENT ADVISORY SERVICES, LLC (425K shares), Kestra Advisory Services, LLC (329K shares), MORGAN STANLEY (287K shares), BlackRock, Inc. (285K shares), GOLDMAN SACHS GROUP INC (196K shares), and 683 Capital Management, LLC (163K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.